Smallpox News and Research

RSS

Smallpox is a highly contagious disease caused by the variola virus, a member of the Orthopox virus family. It is one of the most devastating diseases known to humanity, with a mortality rate as high as 30%. In 1967, the World Health Organization embarked upon an intensified vaccination campaign to eliminate smallpox, which culminated in the successful eradication of the disease globally by 1980.

By the mid-1980s, there were only two known repositories of variola virus: the Institute of Virus Preparations in Russia, and the US CDC. The events in the US in September and October 2001 highlighted the risk that the variola virus might be used as an agent of bioterrorism. Governments around the world are taking precautionary measures to be ready to deal with a potential smallpox outbreak.

Emergent BioSolutions enters into definitive agreement to acquire Cangene

Emergent BioSolutions Inc.announced that it has entered into a definitive agreement with Cangene Corporation (TSX: CNJ) under which Emergent will acquire all of the outstanding common shares of Cangene in an all-cash transaction valued at $3.24 per share on a fully diluted basis for an aggregate purchase price of $222 million.

12 Dec 2013

Edison Investment Research's report examines long-term investment case for Bavarian Nordic

Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine.

6 Dec 2013

Measles still poses threat to domestic and global health security

Fifty years after the approval of an extremely effective vaccine against measles, one of the world's most contagious diseases, the virus still poses a threat to domestic and global health security.

5 Dec 2013

Patients treated by ID physicians less likely to die in hospital

In a first-of-its-kind study to evaluate the impact of a medical specialty on patient outcomes, researchers found that hospitalized patients with severe infections such as meningitis and Clostridium difficile are significantly less likely to die if they receive care from an infectious diseases specialist. The study, which analyzed nearly 130,000 Medicare patient cases, is now available online and will be published in the December 15 issue of Clinical Infectious Diseases.

30 Sep 2013

Group Health helps protect public from infectious diseases through nationwide network

A nationwide group of institutions that conducts clinical trials of promising candidate vaccines and therapies for infectious diseases, known as the Vaccine and Treatment Evaluation Units (VTEUs), has been awarded nine contracts to strengthen and broaden the scope of its research. Group Health Research Institute is one of these institutions.

27 Sep 2013

Cangene Signs Up To $77M Contract Extension With CDC

...

3 Sep 2013

Cangene Inks Up To $77M Contract Extension With CDC

...

3 Sep 2013

Viewpoints: GOP should focus on fixing health law; bishops refuse to accept victory

Los Angeles Times: It's Time To Focus On Fixing The Affordable Care Act, Not Gutting It Conservatives have married their political fortunes to the notion that Obamacare is a catastrophe and must be discarded in its entirety -; even though some of the signature elements of the law, such as a requirement that most people be insured, are ideas that they originated.

15 Jul 2013

Experts report new outbreaks and increased spread of Cassava Brown Streak Disease

Cassava experts are reporting new outbreaks and the increased spread of Cassava Brown Streak Disease or CBSD, warning that the rapidly proliferating plant virus could cause a 50 percent drop in production of a crop that provides a significant source of food and income for 300 million Africans.

6 May 2013

Bill Gates seeks additional $1.5B in donations for polio eradication efforts

Bill Gates, co-chair of the Bill & Melinda Gates Foundation, "is seeking a further $1.5 billion in donations to wipe out polio by 2018 and make it the first infectious disease eradicated since smallpox was wiped from the planet in 1979".

26 Apr 2013

National Foundation for Infectious Diseases to host 16th Annual Conference on Vaccine Research

The National Foundation for Infectious Diseases will host the 16th Annual Conference on Vaccine Research, April 22-24, 2013, at the Hyatt Regency Inner Harbor in Baltimore, MD.

22 Apr 2013

Pneumococcal vaccine: an interview with Graham Clarke, CEO ImmBio

The pathogen that we are talking about is called streptococcus pneumoniae. That is a fairly common bacteria and if you did a nasal swab you would find that quite a lot of people have this bacterium living in their nasal passages.

16 Apr 2013

Experts launch new strategy to eradicate polio by 2018

Hundreds of scientists, doctors and other experts from around the world launched the Scientific Declaration on Polio Eradication today, declaring that an end to the paralyzing disease is achievable and endorsing a comprehensive new strategy to secure a lasting polio-free world by 2018.

12 Apr 2013

Researchers evaluate Pexa-Vec to slow progression of liver cancer

As part of a multicenter clinical trial, researchers at University of California, San Diego School of Medicine are evaluating Pexa-Vec (JX-594) to slow the progression of hepatocellular carcinoma or liver cancer. Pexa-Vec is a genetically engineered virus that is used in the smallpox vaccine.

10 Apr 2013

Clinical data of two Transgene products to be presented at EASL Conference

Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products - TG1050 and TG4040 to treat chronic hepatitis B and chronic hepatitis C, respectively - will be presented in oral presentations at this year's European Association for the Study of the Liver Conference (Amsterdam, Netherlands, April 24-28, 2013).

9 Apr 2013

Finding solutions to protect U.S. troops against invisible killers

A Saint Louis University researcher has received a contract worth up to $980,000 to see if two cancer medications have the potential of protecting U.S. troops from biological agents that could be unleashed during an attack.

4 Apr 2013

Researchers develop new approach for HIV vaccine development

Decades of research and three large-scale clinical trials have so far failed to yield an effective HIV vaccine, in large part because the virus evolves so rapidly that it can evade any vaccine-induced immune response.

22 Mar 2013

Chimerix receives FDA Fast Track designation for CMX001 to prevent CMV infection

Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CMX001 for the prevention of cytomegalovirus (CMV) infection.

12 Mar 2013

Inviragen to initiate second stage of DENVax Phase 2 study in dengue

Inviragen, Inc. today announced the initiation of the second stage of an ongoing Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.

27 Feb 2013

Polio eradication strategy must be adjusted for local contexts

"It has been a particularly busy couple of months for the Global Polio Eradication Initiative (GPEI)," SciDev.Net Director Nick Ishmael Perkins writes in a SciDev.Net editorial. "The deadly attacks on vaccinators in Pakistan brought renewed global attention to the campaign, and then Bill Gates went public with his personal commitment to end polio," he states, adding, "The GPEI has responded with a strategy for what it calls the 'endgame.'"

26 Feb 2013